采用CA1而非整个海马以捕捉tau-PET Braak II期
本研究在TRIAD(N=456)和ADNI(N=497)观察性队列中,使用[18F]MK-6240或[18F]flortaucipir tau-PET及结构MRI,比较CA1特异性Braak II期感兴趣区与全海马方法。结果显示CA1基于Braak II期分类者淀粉样蛋白负担更高、Braak III期tau累积更一致、纵向进展更稳定,且分类不一致和分期回退更少。CA1特异性量化改善Braak II期分类的生物学合理性和纵向一致性。
要点
- 早期海马tau-PET信号主要定位于前部CA1。
- 全海马测量更易受脉络丛污染等脱靶信号影响。
- CA1分期减少分类不一致和随访分期回退。
核心结论
- CA1特异性tau-PET量化通过靶向早期tau病理最易受累的海马亚区并减轻脱靶污染,改善Braak II期分类的生物学合理性和纵向一致性。
研究设计与样本
- 在TRIAD(N=456)和ADNI(N=497)观察性队列中开展横断面和纵向分析,使用[18F]MK-6240或[18F]flortaucipir tau-PET及结构MRI,比较CA1特异性Braak II期感兴趣区与全海马方法。
主要发现
- 空间分析显示早期海马tau-PET信号主要定位于前部CA1。
- 全海马测量更频繁受与脉络丛污染一致的脱靶信号影响。
- CA1基于Braak II期分类者淀粉样蛋白-PET负担更高,Braak III期区域tau累积更一致,纵向进展更稳定。
- CA1基于分期产生更少分类不一致和随访时更少分期回退。
临床怎么用
- 在可用PET分辨率下,CA1特异性tau-PET量化可用于改善早期AD特征描述并支持针对临床前tau累积的试验参与者选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tau-PET enables in-vivo staging of Alzheimer disease (AD) pathology, including early Braak stage II involvement of the hippocampus. Conventional whole-hippocampus definitions combine heterogeneous subfields and are susceptible to off-target signal that varies across tracers, limiting sensitivity, specificity, and longitudinal interpretability of early tau accumulation. METHODS: Cross-sectional and longitudinal analyses were conducted in the TRIAD (N = 456) and the ADNI (N = 497) observational cohorts with tau-PET with [18F]MK-6240 or [18F]flortaucipir and structural MRI. A CA1-specific Braak stage II region of interest was compared with a whole-hippocampus approach. Outcomes included Braak stage concordance, longitudinal stability, tau-PET progression, and biological plausibility assessed by amyloid-PET burden and extrahippocampal tau signal. RESULTS: Spatial analyses localised early hippocampal tau-PET signal predominantly to the anterior CA1. Whole-hippocampus measures were more frequently influenced by off-target signal consistent with choroid plexus contamination. Participants classified as CA1-based Braak stage II showed higher amyloid-PET burden, more consistent tau accumulation in the Braak stage III region, and more stable longitudinal progression. CA1-based staging yielded fewer discordant classifications and fewer stage regressions at follow-up. CONCLUSION: CA1-specific tau-PET quantification improves biological plausibility and longitudinal consistency of Braak stage II classification by targeting the hippocampal subfield most vulnerable to early tau pathology and mitigating off-target contamination. CA1-based Braak stage II participants showed greater coherence with the biological framework of AD than those staged using the whole hippocampus. Applicable to available PET resolution, this approach may enhance characterisation of early AD and support participant selection in trials targeting preclinical tau accumulation.
引用
- Aumont E, Trudel L, Hall BJ, et al. Using CA1 rather than the whole hippocampus to capture tau-PET Braak stage II. Eur J Nucl Med Mol Imaging. 2026. PMID: 42448890. doi:10.1007/s00259-026-08074-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。